Literature DB >> 21925790

Human DNAJ in cancer and stem cells.

Jason N Sterrenberg1, Gregory L Blatch, Adrienne L Edkins.   

Abstract

The heat shock protein 40kDa (HSP40/DNAJ) co-chaperones constitute the largest and most diverse sub-group of the heat shock protein (HSP) family. DNAJ are widely accepted as regulators of HSP70 function, but also have roles as co-chaperones for the HSP90 chaperone machine, and a growing number of biological functions that may be independent of either of these chaperones. The DNAJ proteins are differentially expressed in human tissues and demonstrate the capacity to function to both promote and suppress cancer development by acting as chaperones for tumour suppressors or oncoproteins. We review the current literature on the function and expression of DNAJ in cancer, stem cells and cancer stem cells. Combining data from gene expression, proteomics and studies in other systems, we propose that DNAJ will be key regulators of cancer, stem cell and possibly cancer stem cell function. The diversity of DNAJ and their assorted roles in a range of biological functions means that selected DNAJ, provided there is limited redundancy and that a specific link to malignancy can be established, may yet provide an attractive target for specific and selective drug design for the development of anti-cancer treatments.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21925790     DOI: 10.1016/j.canlet.2011.08.019

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  43 in total

1.  The Role of the Phylogenetically Conserved Cochaperone Protein Droj2/DNAJA3 in NF-κB Signaling.

Authors:  Yoshiki Momiuchi; Kohei Kumada; Takayuki Kuraishi; Takeshi Takagaki; Toshiro Aigaki; Yoshiteru Oshima; Shoichiro Kurata
Journal:  J Biol Chem       Date:  2015-08-05       Impact factor: 5.157

Review 2.  Opportunities and challenges for molecular chaperone modulation to treat protein-conformational brain diseases.

Authors:  Herman van der Putten; Gregor P Lotz
Journal:  Neurotherapeutics       Date:  2013-07       Impact factor: 7.620

3.  RME-8 coordinates the activity of the WASH complex with the function of the retromer SNX dimer to control endosomal tubulation.

Authors:  Caroline L Freeman; Geoffrey Hesketh; Matthew N J Seaman
Journal:  J Cell Sci       Date:  2014-03-18       Impact factor: 5.285

Review 4.  Selective targeting of the stress chaperome as a therapeutic strategy.

Authors:  Tony Taldone; Stefan O Ochiana; Pallav D Patel; Gabriela Chiosis
Journal:  Trends Pharmacol Sci       Date:  2014-09-25       Impact factor: 14.819

5.  HLJ1 (DNAJB4) Gene Is a Novel Biomarker Candidate in Breast Cancer.

Authors:  Tolga Acun; Natalie Doberstein; Jens K Habermann; Timo Gemoll; Christoph Thorns; Emin Oztas; Thomas Ried
Journal:  OMICS       Date:  2017-05

6.  Heat shock proteins in cancer stem cell maintenance: A potential therapeutic target?

Authors:  Giacomo Lettini; Silvia Lepore; Fabiana Crispo; Lorenza Sisinni; Franca Esposito; Matteo Landriscina
Journal:  Histol Histopathol       Date:  2019-07-19       Impact factor: 2.303

Review 7.  Tumour suppressor HLJ1: A potential diagnostic, preventive and therapeutic target in non-small cell lung cancer.

Authors:  Meng-Feng Tsai; Chi-Chung Wang; Jeremy Jw Chen
Journal:  World J Clin Oncol       Date:  2014-12-10

Review 8.  Heat shock proteins 27, 40, and 70 as combinational and dual therapeutic cancer targets.

Authors:  Jeanette R McConnell; Shelli R McAlpine
Journal:  Bioorg Med Chem Lett       Date:  2013-02-13       Impact factor: 2.823

9.  HLJ1 is an endogenous Src inhibitor suppressing cancer progression through dual mechanisms.

Authors:  C-H Chen; W-H Chang; K-Y Su; W-H Ku; G-C Chang; Q-S Hong; Y-J Hsiao; H-C Chen; H-Y Chen; R Wu; P-C Yang; J J W Chen; S-L Yu
Journal:  Oncogene       Date:  2016-04-11       Impact factor: 9.867

Review 10.  Hsp70 protein complexes as drug targets.

Authors:  Victoria A Assimon; Anne T Gillies; Jennifer N Rauch; Jason E Gestwicki
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.